Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines

Chayama, Kazuaki; Hayes, C.; Ohishi, Waka; Kawakami, Yoshiiku
January 2013
Journal of Gastroenterology;Jan2013, Vol. 48 Issue 1, p1
Academic Journal
Hepatitis C virus (HCV) infection is a serious health problem leading to cirrhosis, liver failure and hepatocellular carcinoma. The recent introduction of telaprevir, which was approved in November 2011, in combination with peg-interferon and ribavirin is expected to markedly improve the eradication rate of the virus. However, side effects of triple therapy may be severe. In a phase three III clinical trial, 2250 mg of telaprevir, which is the same dosage used in clinical trials in Western countries, was given to Japanese patients. As this dosage is considered to be relatively high for Japanese patients, who typically have lower weight than patients in Western countries, reduction of telaprevir is recommended in the 2012 revision of the guidelines established by the Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis published by the Ministry of Health, Labour and Welfare of Japan. Other protease inhibitors with fewer side effects are now in clinical trials in Japan. Alternatively, treatment of patients with combination of direct acting antivirals without interferon has been reported. In this review we summarize current treatment options in Japan and discuss how we treat patients with chronic HCV infection.


Related Articles

  • Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C. Kagawa, Tatehiro; Keeffe, Emmet B. // Hepatitis Research & Treatment;2010, p1 

    Chronic hepatitis C is a major cause of chronic liver disease globally, and the natural history of progression may lead to cirrhosis with liver failure, hepatocellular carcinoma, and premature liver-related death. Emerging data demonstrates that interferon-based therapy, particularly among those...

  • Antiviral Therapy for Hepatitis C Prophylaxis in Percutaneous Exposure and Acute Hepatitis C. Martalena, Dewi; Kurniawan, Juferdy // Indonesian Journal of Gastroenterology, Hepatology & Digestive E;Aug2012, Vol. 13 Issue 2, p103 

    Incidence of percutaneous exposure to hepatitis C virus (HCV) is still quite high, particularly in medical staffs. Though not all will cause infection, but if acute HCV infection occurs, it usually develops into chronic hepatitis which finally causes cirrhosis and hepatocellular carcinoma....

  • Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection. Fernández-Yunquera, Ainhoa; Rincón, Diego; Salcedo, Magdalena; Bañares, Rafael // Revista Española de Quimioterapia;sep2013, Vol. 26 Issue 3, p189 

    No abstract available.

  • Early detection of unhealthy behaviors, the prevalence and receipt of antiviral treatment for disabled adult hepatitis B and C carriers. Sui-Whi Jane; Ming-Shyan Lin; Wen-Nan Chiu; Li-Ju Lai; Po-Han Chen; Mei-Yen Chen; Jane, Sui-Whi; Lin, Ming-Shyan; Chiu, Wen-Nan; Lai, Li-Ju; Chen, Po-Han; Chen, Mei-Yen // BMC Public Health;2/13/2016, Vol. 16 Issue 1, p1 

    Background: Evidence indicates that hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the leading causes of liver cirrhosis and hepatocellular carcinoma. Antiviral treatments have recently been reported as successful cures. However, the prevalence rates of HBV or...

  • Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C. Pfeil, Alena M.; Reich, Oliver; Guerra, Ines M.; Cure, Sandrine; Negro, Francesco; Müllhaupt, Beat; Lavanchy, Daniel; Schwenkglenks, Matthias // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    In clinical trials, sofosbuvir showed high antiviral activity in patients infected with hepatitis C virus (HCV) across all genotypes. We aimed to determine the cost-effectiveness of sofosbuvir-based treatment compared to current standard treatment in mono-infected patients with chronic hepatitis...

  • Treating hepatitis C - what's new? Thompson, Alex J.; Holmes, Jacinta A. // Australian Prescriber;Dec2015, Vol. 38 Issue 6, p191 

    Chronic hepatitis C infection causes cirrhosis, liver failure and hepatocellular carcinoma, and is the most common indication for liver transplantation. Hepatitis C is curable and complications can be prevented. Until recently, treatment regimens involved peginterferon alfa. Although effective,...

  • Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. del Carmen Manzano-Robleda, María; Ornelas-Arroyo, Victoria; Barrientos-Gutiérrez, Tonatíuh; Méndez-Sánchez, Nahum; Uribe, Misael; Chávez-Tapia, Norberto C. // Annals of Hepatology: Official Journal of the Mexican Associatio;Jan/Feb2015, Vol. 14 Issue 1, p46 

    Background. Treatment of hepatitis C virus (HCV) infection with newer direct-acting antivirals is unrealistic in some countries because of the lack of availability. Aim. Assess benefits and harms of boceprevir (BOC) and telaprevir (TLV) in treatment of genotype 1 HCV infection, and identifying...

  • Hepatitis C Direct Antiviral Drugs and Hepatic Decompensation in Patients with Advanced Cirrhosis: Culprit or Innocent Bystander? Saxena, Varun; Terrault, Norah // Digestive Diseases & Sciences;Apr2015, Vol. 60 Issue 4, p806 

    No abstract available.

  • Telaprevir.  // Reactions Weekly;7/6/2013, Issue 1460, p39 

    The article presents the case studies of two women with anaemia, who received telaprevir, peginterferon-α-2b and ribavirin triple therapy for the treatment of chronic hepatitis C.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics